Skip to main content

Teva Pharmaceutical Value Stock - Dividend - Research Selection

Teva pharmaceutical

ISIN: US8816242098 , WKN: 883035

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment\'s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-09-09
Discover Teva’s growth strategy, innovative biopharma pipeline, and outlook from the

Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2025 Update

2025-09-02
Duquesne Family Office's Q2 2025 portfolio updates: key bets in tech & healthcare, new positions, and Druckenmiller's trend-driven investment strategy. See more.

Wall Street Lunch: 'Economy Is Slowing, But Still Clearly Growing'

2025-08-28
Lumber futures on edge of bear territory; Snowflake, HP gaining post-earnings; U.S. GDP growth revised higher.

Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue

2025-08-28
Teva offers strong value upside through disciplined execution and does not require growth surprise. Read more on TEVA stock is a Buy.

Teva Pharmaceutical: Tariff Relief Clears The Way For Reinvention

2025-08-22
Explore Teva Pharmaceutical Industries Limited's turnaround as branded drugs boost margins, generics stabilize, and biosimilars promise growth. Click for more.

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

2025-07-31
Teva's transformation boosts profit growth and specialty drugs, offering an undervalued opportunity. Click here to read my most recent analysis of TEVA stock.

Alkermes: A More Than Solid Quarter

2025-07-30
Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress. Click to read why ALKS is a Hold.

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

2025-07-30
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ETCompany ParticipantsChristopher J.

Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1

2025-07-18
(Bloomberg) -- President Donald Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two weeks, ramping up his push to reshape the US’s standing in the global trading system by penalizing purchases from abroad.Most Read from BloombergThe Dutch Intersection Is Coming to Save Your LifeMumbai Facelift Is Inspired by 200-Year-Old New York BlueprintAdvocates Fear US Agents Are Using ‘Wellness Checks’ on Children as a Prelude to ArrestsLA Homeless

JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise

2025-07-16
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.